Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.57 |
| ▸ | BACE1 | P56817 | 11/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.44 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.38 |
| ▸ | CHRNG | P07510 | 1/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | CHRND | Q07001 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6004350 | 0.82 | CYP19A1 (0.53) | CYP19A1BACE1CTSDBACE2HSD11B1 | |
| SCHEMBL11076987 | 0.82 | CYP19A1 (0.72) | CYP19A1BACE1CTSDBACE2 | |
| SCHEMBL11078445 | 0.82 | CYP19A1 (0.71) | CYP19A1BACE1CTSDBACE2 | |
| SCHEMBL4771129 | 0.81 | CYP19A1 (0.58) | CYP19A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11079440 | 0.81 | CYP19A1 (0.55) | CYP19A1BACE1CTSDBACE2SLC6A2 | |
| SCHEMBL4190208 | 0.78 | CYP19A1 (0.62) | CYP19A1BACE1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4194637 | 0.77 | CYP19A1 (0.50) | CYP19A1BACE1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4184614 | 0.76 | CYP19A1 (0.59) | CYP19A1BACE1CTSDBACE2 | |
| SCHEMBL4181298 | 0.73 | CYP19A1 (0.59) | CYP19A1BACE1 | |
| SCHEMBL2779577 | 0.73 | CYP19A1 (1.00) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | DOV PHARMACEUTICAL, INC. | 2006-10-05 | — | — | US | disclosed |
| US-4435419-A | Method of treating depression using azabicyclohexanes | AMERICAN CYANAMID COMPANY (US) | 1984-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | HTR1B, SLC6A3, CYP1B1 | CYP19A1 461/4885BACE1 469/4885CTSD 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.